43rd Annual Miami Breast Cancer Conference® - Abstracts

In 50,845 SEER patients aged ≥70 years with stage I ER-positive breast cancer after BCS, radiation omission was not associated with inferior BCSS (aHR, 0.95; 95% CI, 0.87-1.04), though radiation conferred modest OS benefit, supporting selective de-escalation in older patients.

Using the DISCERN tool, LLMs (ChatGPT and OpenEvidence) scored significantly higher than Google on breast pathology health information quality and reliability, with mean total DISCERN scores of 62.2 and 64.8 vs 35.9, supporting integration of AI tools for patient education.

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

In 278 patients with a positive family history of breast cancer followed for a median 96 months, local recurrence, regional recurrence, and CBC risk were comparable to general population rates by SIR analysis, with recurrence risk driven more by biological subtype than family history.

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

In this institutional retrospective review, 14.4% of clinically node-negative patients meeting SOUND trial criteria had nodal metastases on SLNB, underscoring the need for careful multidisciplinary decision-making before integrating axillary staging de-escalation into practice.

In 167 patients with HR+/HER2− breast cancer after neoadjuvant chemotherapy, lymphovascular invasion, number of positive sentinel nodes, and >50% positive sentinel nodes were the strongest predictors of high axillary burden; a nomogram was developed to guide axillary management decisions.

A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo simulation showing an 80% probability of ICG superiority.